Download Free Diabetes Hypertension And Cardiovascular Disease Book in PDF and EPUB Free Download. You can read online Diabetes Hypertension And Cardiovascular Disease and write the review.

Diabetes and hypertension have evolved as two of the modern day epidemics affecting millions of people around the world. These two common co-morbidities lead to substantial increase in cardiovascular disease, the major cause of morbidity and mortality of adults around the world. In Diabetes and Hypertension: Evaluation and Management, a panel of renowned experts address a range of critical topics -- from basic concepts in evaluation and management of diabetes and hypertension, such as dietary interventions, to evaluation and management of secondary hypertension in clinical practice. Other chapters focus on high cardiovascular risk populations such as those with coronary heart disease, chronic kidney disease and minority patients. In addition, evolving concepts and new developments in the field are presented in other chapters, such as prevention of type 2 diabetes and the epidemic of sleep apnea and its implication for diabetes and hypertension evaluation and management. An important title covering two of the most troubling disorders of our time, Diabetes and Hypertension: Evaluation and Management will provide the busy practitioner with cutting edge knowledge in the field as well as practical information that can translate into better care provided to the high-risk population of diabetics and hypertensive patients.
Diabetes and Cardiovascular Disease: Evaluation, Prevention & Management presents the epidemiologic relation of diabetes and associated risk factors with cardiovascular disease. This concise guide demonstrates the role of non-invasive imaging strategies for evaluation of cardiovascular disease risk in diabetes, and the role of nutrition and physical activity in preventing diabetes and its cardiovascular complications. Diabetes and Cardiovascular Disease: Evaluation, Prevention & Management also covers the relation of chronic kidney disease to diabetes and cardiovascular consequences, and offers glycaemic control strategies for reducing the risk of cardiovascular disease with diabetes. The wide scope of this book makes it an essential resource for diabetologists, cardiologists and physicians. Key Features Presents the relationship between diabetes and cardiovascular disease Focus on prevention and management, including chapter on quality of care and provider/medical systems in diabetes management Edited by team of experts in the field from the University of California
This book provides comprehensive analysis into individualized patient care, and applying evidence‐based medicine while integrating basic medical knowledge with applied medicine. The Editor and the contributors not only discuss important issues on hypertension management and its deleterious consequences if it is not well‐controlled, but also highlight the important signaling pathways involved in the pathogenesis of hypertensive heart disease and cardiac hypertrophy.
Arterial hypertension, coronary heart disease and heart fail ure are the commonest cardiovascular conditions to present in clinical practice. Over the past few years it has become in creasingly clear that they are closely and causally interrelated and that their relationship can have a significant bearing on prognosis. Epidemiological studies have shown that arterial hypertension is one of the most important risk factors for de veloping heart failure. Only one in four patients with hyper tension is adequately managed, and in 50% of cases, the hypertension has not been recognised or treated. Patients with pre-existing hypertension who go on to suffer an acute myocardial infarction have usually not previously had typi cal angina symptoms, the infarct territory is larger, life threatening arrhythmias are commoner and hence in-hospi tal mortality and long-term prognosis are markedly worse. The presence of raised blood pressure in the post-infarct phase doubles the risk of manifest heart failure. The close relationship between hypertension, coronary heart disease and heart failure makes the choice of therapeu tic strategy particularly important. Agents and classes of agents that have prognostic value in all three conditions should be considered first, as synergy might result in addi tional benefits. In such patients, this sort of therapeutic deci sion-making might have further advantages. The use of these agents may prevent complications which are not yet clinically obvious (such as heart failure).
Cardiovascular disease (CVD) encompasses a range of disorders affecting the heart and blood vessels, including coronary heart disease, cerebrovascular disease, and conditions such as aortic aneurysm and lower extremity peripheral artery disease. It remains the leading cause of death worldwide, claiming 17.9 million lives annually, despite the availability of numerous therapeutic drugs. Thus, further research is warranted to enhance CVD treatment and reduce its morbidity and mortality. Diabetes and hypertension are conditions commonly found in aging populations that share common pathogenic pathways and are both strong, independent risk factors for CVD. Reducing blood glucose and blood pressure levels can significantly contribute to mitigating CVD-related morbidity and mortality. This Special Issue aims to present the latest perspectives and research findings on diabetes, hypertension, and CVD, comprising one Editorial article, eight review articles, and eight original research articles. These articles provide a comprehensive overview of recent developments in research on hypertension, insulin resistance/diabetes, and CVD, including atherosclerosis, aortic aneurysm, and myocardial infarction. They offer insights into CVD pathogenesis and facilitate the development of new therapeutic approaches.
Diabetes and cardiovascular disease together account for the largest portion of health care spending compared to all other diseases in Western society. This work seeks to provide an understanding of the causes of diabetes and its cardiovascular complications. As this understanding becomes more widely appreciated, it will serve as a foundation for evidence-based care and wider acceptance of sound science. The International Conference on Diabetes and Cardiovascular Disease, held in Winnipeg, in June 1999, was organized to bring together a multi-disciplinary group of researchers dedicated to further knowledge amongst researchers, care givers, and the managers of the health system. The invited speakers submitted their works for publication, which serves as the basis for this book. Major themes include: epidemiology of diabetes mellitus, metabolic risk factors in diabetes and cardiovascular disease, hypertension in diabetes mellitus, cardiac function in diabetes, glycemic control and improved cardiovascular function, diabetes management, and endothelial function in diabetes.
Phytotherapy in the Management of Diabetes and Hypertension is a good addition to existing volumes detailing knowledge of hyperglycemia therapy. This e-book emphasizes the basic biochemistry behind diabetes mellitus and hypertension, along with the control or remediation of these conditions through a cost effective, safe, easy-going, easy-adaptable method validated by scientific research. This e-book contains 7 chapters dealing with various aspects of these diseases and their Phytotherapy treatment and life style management. Phytotherapy can give patients long term benefits with less or no side effects. Hence, this e-book is an authentic alternative or complementary therapeutic compendium to physicians and patients. This book will also be useful to students, teachers, researchers, clinicians and general readers interested in learning about applied phytotherapy.
Cardiovascular diseases (CVD) are the leading causes of mortality in patients with diabetes, and many factors, including hypertension, contribute to this high prevalence of CVD. The current evidence regarding these diseases is quickly expanding, especially in the vascular mechanisms that predispose someone to both conditions. Furthermore, several novel therapies, such as sodium glucose co-transporter 2 inhibitors, have recently beenshown to have benefits against CVD in patients with type 2 diabetes. With these reasons in mind, the need for updated clinical studies in these fields to optimize the outcomes of patients with diabetes, hypertension, and cardiovascular diseases arises. Finally, as we know that diabetes, hypertension, and especially CVD are associated with severity and mortality in patients with COVID-19 infection, we also invited colleagues around the world to report their clinical insights with these comorbidities and COVID-19 in order to provide support in this fundamental area during the pandemic.